论文部分内容阅读
目的探讨塞来昔布对肿瘤放射治疗的增敏作用。方法选取2014年1月至2015年6月间德阳市第二人民医院收治的60例肿瘤患者,采用随机数法分为观察组和对照组,每组30例。观察组患者采用塞来昔布辅助放射治疗,对照组患者采用单纯放射治疗。比较两组患者临床疗效及不良反应。结果观察组原发灶退缩有效率83.3%,淋巴结退缩有效率78.9%,较对照组的70.0%和66.7%,差异无统计学意义(P>0.05)。所有患者均出现放射性皮炎,观察组胃肠道反应、白细胞减少和肝功能异常发生率分别为10.0%、10.0%和0.0%,较对照组的6.7%、10.0%和3.3%差异均无统计学意义(均P>0.05)。结论塞来昔布辅助放射治疗肿瘤的疗效、不良反应与单纯放疗类似,即塞来昔布对放射增敏作用不明显。
Objective To investigate the sensitizing effect of celecoxib to tumor radiotherapy. Methods Sixty patients with cancer who were treated in Deyang Second People’s Hospital from January 2014 to June 2015 were randomly divided into observation group and control group with 30 cases in each group. Patients in the observation group received celecoxib assisted radiotherapy and patients in the control group received radiotherapy alone. The clinical efficacy and adverse reactions of the two groups were compared. Results In the observation group, the effective rate of primary tumor retraction was 83.3%, the effective rate of lymph node regression was 78.9%, which was 70.0% and 66.7% compared with that of the control group. There was no significant difference (P> 0.05). Radiation dermatitis was observed in all patients. Gastrointestinal reactions, leukopenia and hepatic dysfunction in the observation group were 10.0%, 10.0% and 0.0% respectively, with no statistical difference compared with 6.7%, 10.0% and 3.3% of the control group Significance (all P> 0.05). Conclusion Celecoxib adjuvant radiotherapy of cancer efficacy, adverse reactions and radiotherapy alone is similar, that celecoxib radiosensitization is not obvious.